The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 31, 2010

Filed:

Jan. 24, 2007
Applicants:

Dirk Jan Elbertus Opstelten, Oegstgeest, NL;

Johan Christiaan Kapteyn, Wageningen, NL;

Petrus Christianius Johannes Josephus Passier, Driebergen, NL;

Ronald Hendrik Peter Brus, Voorschoten, NL;

Abraham Bout, Moerkapelle, NL;

Inventors:

Dirk Jan Elbertus Opstelten, Oegstgeest, NL;

Johan Christiaan Kapteyn, Wageningen, NL;

Petrus Christianius Johannes Josephus Passier, Driebergen, NL;

Ronald Hendrik Peter Brus, Voorschoten, NL;

Abraham Bout, Moerkapelle, NL;

Assignee:

Crucell Holland B.V., Leiden, NL;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12N 5/00 (2006.01); C12N 15/00 (2006.01); G01N 33/53 (2006.01); C07K 14/475 (2006.01);
U.S. Cl.
CPC ...
Abstract

Described are methods for identifying, selecting, and obtaining mammalian cells capable of producing proteinaceous molecules having predetermined post-translational modifications, wherein the post-translational modifications are brought about by the mammalian cell in which the proteinaceous molecule is expressed. Preferably, the predetermined post-translational modifications include glycosylation. Also described are methods for obtaining and producing proteinaceous molecules, using mammalian cells obtainable by a method of the present invention. Preferably, the proteinaceous molecules include erythropoietin (EPO), since EPO's effect depends heavily on its glycosylation pattern. Mammalian cells that have been obtained on the basis of their ability to produce proteins and/or post-translational modifications that are indicative for a predetermined post-translational modification that is desired are also provided. Preferably, the mammalian cells have neural characteristics and properties such that significant amounts of recombinant proteins can be produced that harbor 'neural- or brain-type' properties.


Find Patent Forward Citations

Loading…